The Struggles of being a Rare Disease Patient in China

The State of Rare Diseases in China The Illness Challenge Foundation (ICF) is an organization devoted to easing the burdens that rare disease patients living in China face. They accomplish this…

Continue Reading The Struggles of being a Rare Disease Patient in China

How Changing to Outcome-Based Reimbursement Models is Better for Rare Disease Patients

Shifting Contracts Over the years the United States healthcare system has shifted more toward reimbursement models that are outcome-based instead of service-based. In essence, this means that instead of paying…

Continue Reading How Changing to Outcome-Based Reimbursement Models is Better for Rare Disease Patients
First Patient Enrolled in Phase 2 Trial for Experimental RRMS Drug
source: pixabay.com

First Patient Enrolled in Phase 2 Trial for Experimental RRMS Drug

According to a publication from Multiple Sclerosis News Today, German biotechnology company Immunic Therapeutics has successfully enrolled the first participant for its phase 2 clinical trial for experimental relapsing-remitting multiple…

Continue Reading First Patient Enrolled in Phase 2 Trial for Experimental RRMS Drug
Study Shows We Need Better Awareness of Pediatric Onset Multiple Sclerosis to Improve Patient Care
source: pixabay.com

Study Shows We Need Better Awareness of Pediatric Onset Multiple Sclerosis to Improve Patient Care

Multiple Sclerosis (MS) was long believed to be an illness that could only affect adults. In fact, the pediatric form of this disease was not discovered until just over 10…

Continue Reading Study Shows We Need Better Awareness of Pediatric Onset Multiple Sclerosis to Improve Patient Care

You Can Provide Suggestions for the FDA’s Revision of their Rare Disease Research Guidelines

Time for Revision Like many things in this world, research for rare diseases such as Spinal Muscular Atrophy (SMA), Multiple Sclerosis, and Duchenne Muscular Dystrophy (DMD) has evolved substantially in recent years. This evolution…

Continue Reading You Can Provide Suggestions for the FDA’s Revision of their Rare Disease Research Guidelines